FDA approves D-VRd quadruplet for transplant-ineligible newly diagnosed multiple myeloma based on CEPHEUS trial PFS and MRD negativity gains.
Updates on recent FDA approvals, label expansions, and regulatory decisions that may affect everyday oncology practice.
